- Home
- TDC vs VRDN Comparison
TDC vs VRDN Comparison
Compare TDC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDC | VRDN |
|---|---|---|
| Founded | 1979 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | TDC | VRDN |
|---|---|---|
| Price | $29.80 | $30.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $30.13 | ★ $40.45 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 02-10-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.18 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $1,651,000,000.00 | $70,789,000.00 |
| Revenue This Year | N/A | $26,257.62 |
| Revenue Next Year | N/A | $10.69 |
| P/E Ratio | $25.18 | ★ N/A |
| Revenue Growth | N/A | ★ 23340.07 |
| 52 Week Low | $18.43 | $9.90 |
| 52 Week High | $33.03 | $34.04 |
Technical Indicators
Market Signals| Indicator | TDC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 46.96 |
| Support Level | $30.41 | $30.57 |
| Resistance Level | $31.16 | $32.92 |
| Average True Range (ATR) | 0.69 | 1.00 |
| MACD | -0.27 | -0.43 |
| Stochastic Oscillator | 22.16 | 7.59 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).